All articles by Robert G. Uzzo, MD, FACS
We crave clinical and scientific data, yet we grieve the performance-based data increasingly directed toward us.
The term “personalized medicine” remains an overused promise to apply specific treatment plans.
For men at risk of developing prostate cancer (PCa), prophylactic prostatectomy seems almost irrational for several reasons
Physicians are more often defined by their ability to diagnose, treat, and research a disease than their willingness to manage its spectrum of risk.
Radical cystectomy with urinary diversion including neobladder remains the standard of care for muscle-invasive bladder cancer.
Although data suggest that cancer rates are also higher in obese patients, the associations are largely based on observational/population studies.
Cross-sectional imaging now substitutes for physical diagnosis in most emergency rooms.
Risk-stratifying patients requires a urologist’s understanding of the natural history of disease, competing risks, and morbidities of interventions.
More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
Individuals, businesses and nations grapple with how to measure success. Are similar productivity measures warranted in medicine?
Next post in Commentary